CT Abdomen and Pelvis Without IV Contrast There is limited evidence to support the use of CT abdomen and pelvis without IV contrast for initial imaging of patients with clinically suspected prostate cancer and no prior biopsy. CT Chest, Abdomen, and Pelvis With IV Contrast There is limited evidence to support the use of CT chest, abdomen, and pelvis with IV contrast for initial imaging of patients with clinically suspected prostate cancer and no prior biopsy. CT Chest, Abdomen, and Pelvis Without and With IV Contrast There is limited evidence to support the use of CT chest, abdomen, and pelvis without and with IV contrast for initial imaging of patients with clinically suspected prostate cancer and no prior biopsy. CT Chest, Abdomen, and Pelvis Without IV Contrast There is limited evidence to support the use of CT chest, abdomen, and pelvis without IV contrast for initial imaging of patients with clinically suspected prostate cancer and no prior biopsy. FDG-PET/CT Whole Body Because prostate cancer and metastases from it are generally not fluorine-18-2-fluoro-2-deoxy-D-glucose (FDG)- avid unlike most other malignancies, FDG-PET/CT may not be beneficial as part of initial imaging. FDG-PET/MRI Skull Base to Mid-Thigh Because prostate cancer and metastases from it are generally not FDG-avid unlike most other malignancies, FDG- PET/MRI may not be beneficial as part of initial imaging. Fluciclovine PET/CT Skull Base to Mid-Thigh There is limited evidence to support the use of fluciclovine PET/CT for initial imaging of patients with clinically suspected prostate cancer and no prior biopsy. Fluciclovine PET/MRI Skull Base to Mid-Thigh There is limited evidence to support the use of fluciclovine PET/MRI for initial imaging of patients with clinically suspected prostate cancer and no prior biopsy.
Pretreatment Detection Surveillance and Staging of Prostate Cancer. CT Abdomen and Pelvis Without IV Contrast There is limited evidence to support the use of CT abdomen and pelvis without IV contrast for initial imaging of patients with clinically suspected prostate cancer and no prior biopsy. CT Chest, Abdomen, and Pelvis With IV Contrast There is limited evidence to support the use of CT chest, abdomen, and pelvis with IV contrast for initial imaging of patients with clinically suspected prostate cancer and no prior biopsy. CT Chest, Abdomen, and Pelvis Without and With IV Contrast There is limited evidence to support the use of CT chest, abdomen, and pelvis without and with IV contrast for initial imaging of patients with clinically suspected prostate cancer and no prior biopsy. CT Chest, Abdomen, and Pelvis Without IV Contrast There is limited evidence to support the use of CT chest, abdomen, and pelvis without IV contrast for initial imaging of patients with clinically suspected prostate cancer and no prior biopsy. FDG-PET/CT Whole Body Because prostate cancer and metastases from it are generally not fluorine-18-2-fluoro-2-deoxy-D-glucose (FDG)- avid unlike most other malignancies, FDG-PET/CT may not be beneficial as part of initial imaging. FDG-PET/MRI Skull Base to Mid-Thigh Because prostate cancer and metastases from it are generally not FDG-avid unlike most other malignancies, FDG- PET/MRI may not be beneficial as part of initial imaging. Fluciclovine PET/CT Skull Base to Mid-Thigh There is limited evidence to support the use of fluciclovine PET/CT for initial imaging of patients with clinically suspected prostate cancer and no prior biopsy. Fluciclovine PET/MRI Skull Base to Mid-Thigh There is limited evidence to support the use of fluciclovine PET/MRI for initial imaging of patients with clinically suspected prostate cancer and no prior biopsy.